The efficacy of trametinib, a MEK1/2 inhibitor, has been demonstrated in a single patient case of RAS-related CLAs and in a KRAS-driven mouse model of Gorham-Stout disease (12, 20–23). Here, KRAS is linked to Gorham-Stout disease.